F-1/A: Zhong Yuan Bio-Technology Holdings Eyes Nasdaq Listing with 1.1 Million Share Offering

Zhong Yuan Bio-Technology Holdings is seeking to list on the Nasdaq Capital Market through a public offering of 1.1 million ordinary shares, while also registering 1 million shares for potential resale by a major shareholder.

Summary

• Zhong Yuan Bio-Technology Holdings Limited is attempting to list its ordinary shares on the Nasdaq Capital Market.
• The company is offering 1,100,000 ordinary shares in a firm commitment offering.
• The anticipated public offering price is between US$5.00 and US$7.00 per share.
• The company's ordinary shares previously traded on the OTC Market under the symbol ZHYBF.
• The company will not proceed with the offering unless Nasdaq approval is obtained.
• An additional 1,000,000 ordinary shares are being registered for potential resale by Mr. Yu Chang, with the company receiving no proceeds from these sales.
• The company is incorporated in the Cayman Islands and conducts operations in China through its subsidiaries.
• The company is subject to potential regulatory oversight by the Chinese government and faces risks related to the Holding Foreign Companies Accountable Act (HFCAA).
• The company's independent auditor, Centurion ZD CPA & Co., is headquartered in Hong Kong.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced reporting requirements.
• Net proceeds from the offering are intended for research and development of new drugs for neurological diseases and for working capital.
• Assuming a public offering price of US$6.00 per Ordinary Share, the company expects to receive net proceeds of US$6,138,000, before expenses, assuming the underwriters do not exercise any part of their over-allotment option.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. The company is pursuing a Nasdaq listing and has plans for future growth, but it also faces regulatory risks, has a limited operating history, and has identified material weaknesses in its internal control over financial reporting.

Positives

• The company is pursuing a Nasdaq listing, which could increase visibility and access to capital.
• Proceeds from the offering will be used for research and development, potentially leading to new products and revenue streams.
• The company has a cooperation agreement with the Wengniuteqi District government for Acer truncatum seeds.
• The company holds 19 invention patents, 2 PCT patents and 18 computer software copyrights related to its research.

Negatives

• The company is subject to regulatory risks in China, including potential intervention by the Chinese government.
• The company faces potential delisting under the HFCAA if the PCAOB cannot inspect its auditor.
• The company has a limited operating history and has experienced negative cash flow and losses from operations.
• The company is dependent on a limited number of products for its revenue.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The Chinese government may exercise significant oversight and discretion over the company's business.
• The company may be subject to PRC laws regarding data security or securities offerings.
• Changes in international trade policies and geopolitical conflicts may have an adverse effect on the company's business.
• The company may not be able to maintain the listing of its ordinary shares on the Nasdaq Capital Market.
• The trading price of the company's shares may be volatile.
• The company does not expect to pay dividends in the foreseeable future.
• The company is controlled by its principal shareholders, whose interests may differ from those of other shareholders.
• The company is an emerging growth company and may take advantage of certain reduced reporting requirements.
• The company may be classified as a passive foreign investment company, which could have adverse tax consequences for U.S. shareholders.
• It may be difficult to enforce judgments against the company and its management.

Future Outlook

The company intends to use the net proceeds from this offering for research and development of new drugs for neurological diseases and for working capital and other general corporate purposes.

Industry Context

The document highlights the growing market for nervonic acid health supplements, particularly targeting the aging population, and notes that the industry is in its early stages with limited current competition.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Shareholders may benefit from the company's increased visibility and access to capital if the Nasdaq listing is successful.
• The company's employees may benefit from increased investment in research and development and potential growth of the company.
• Customers may benefit from the development of new products and services.

Next Steps

• Obtain approval from the Nasdaq Stock Market to list the ordinary shares.
• Complete the public offering and deliver the ordinary shares to purchasers.
• File with the CSRC within three working days after completion of this offering.
• Utilize net proceeds for research and development and working capital.

Key Dates

Keywords

Zhong Yuan Bio-Technology, Nasdaq, Public Offering, HFCAA, China, Nervonic Acid, Emerging Growth Company, PCAOB, Ordinary Shares, Listing